Oncology | Page 5 of 7 | www.PharmaNewsDaily.com

Home » Posts tagged with » Oncology (Page 5)

Five Prime, Zai Lab initiate phase 3 trial of bemarituzumab chemo combo

October 1, 2018 No Comment

Five Prime Therapeutics and Zai Lab have dosed the first patient in a phase 3 study of bemarituzumab (FPA144) in combination with chemotherapy in patients having advanced gastric cancer (GC) or gastroesophageal junction (GEJ) cancer. The late-stage trial named as FIGHT features advanced gastric cancer or gastroesophageal junction cancer patients who were not subjected to […]

Trovagene updates on acute myeloid leukemia trial for Onvansertib

September 29, 2018 No Comment

Trovagene, a California-based cancer research company, said that it has wrapped up the second dosing cohort of the Onvansertib-decitabine combination, in a phase 1b/2 acute myeloid leukemia trial. Onvansertib is said to be a highly-selective oral Polo-like Kinase 1 (PLK1) inhibitor. Designed to be orally administered, Onvansertib has a 24-hour drug half-life. According to Trovagene, […]

MedGenome says cancer vaccine approach can help in Lynch Syndrome treatment

September 15, 2018 No Comment

MedGenome, an Indian genomics research and diagnostics startup, in a recent study has found out that using a cancer vaccine approach can be applied in Lynch Syndrome treatment. The study conducted by MedGenome examined the feasibility of a personalized cancer vaccine approach by detecting potential immunogenic tumor specific alterations. Lynch Syndrome or hereditary non-polyposis colorectal […]

Boehringer Ingelheim acquires oncolytic virus company ViraTherapeutics

September 15, 2018 No Comment

German pharma company Boehringer Ingelheim has exercised its option to acquire 100% of Austria-based oncolytic virus company ViraTherapeutics for €210 million in a move to develop next generation viral-based immuno-oncology therapies. In September 2016, Boehringer Ingelheim and ViraTherapeutics entered into a long term collaboration to develop the oncolytic virus therapy platform and also to investigate […]

FDA approves AstraZeneca’s Lumoxiti for hairy cell leukaemia treatment

September 14, 2018 No Comment

Lumoxiti FDA approval : AstraZeneca has bagged the US Food and Drug Administration (FDA) approval for its CD22-directed cytotoxin Lumoxiti (moxetumomab pasudotox-tdfk) for the treatment of relapsed or refractory hairy cell leukaemia (HCL). Lumoxiti FDA approval for hairy cell leukaemia treatment is for adult patients who had undergone more than two systemic therapies in the […]

Oncternal begins phase 1b trial of breast cancer drug cirmtuzumab and paclitaxel combo

September 13, 2018 No Comment

US oncology company Oncternal Therapeutics said that the first patient enrolled in a phase 1b trial of its investigational breast cancer drug cirmtuzumab in combination with paclitaxel, a standard-of-care chemotherapy drug, has been dosed. The phase 1b trial is evaluating the anti-ROR1 monoclonal antibody cirmtuzumab combination with paclitaxel, in breast cancer patients who are negative […]

Merck bags EU approval for Keytruda chemo combo therapy for NSCLC

September 12, 2018 No Comment

Merck has bagged the European Commission approval for the combination of its anti-PD-1 cancer immunotherapy Keytruda (pembrolizumab) with Lilly’s chemotherapy drug pemetrexed (ALIMTA) and platinum chemotherapy for the treatment of a certain form of metastatic nonsquamous non-small cell lung cancer (NSCLC). The latest Keytruda approval is for the use of the cancer combination therapy as […]

Alkermes to evaluate ALKS 4230, pembrolizumab combo for solid tumors

September 11, 2018 No Comment

Irish biopharma company Alkermes said that it has expanded an ongoing phase 1 trial for its immuno oncology drug ALKS 4230 to assess its safety and anti-tumor activity in combination with Merck’s PD-1 inhibitor KEYTRUDA (pembrolizumab) in advanced solid tumors. According to Alkermes, ALKS 4230 is an engineered fusion protein which selectively binds and signals […]

New US biotech company Twentyeight-Seven Therapeutics launched with $65m funding

September 9, 2018 No Comment

A new US biotech company called Twentyeight-Seven Therapeutics (28-7) has been launched in Cambridge, which will focus on modulating non-coding RNA (ncRNA) biology to develop therapies for cancer and other diseases. Twentyeight-Seven Therapeutics has raised $65 million in a Series A financing round coinciding with its launch with founding investor MPM Capital and Novartis Venture […]

Compugen kickstarts phase 1 trial of cancer immunotherapy COM701

September 8, 2018 No Comment

Israeli pharma company Compugen has dosed the first patient in the phase 1 clinical trial which is evaluating the company’s cancer immunotherapy antibody COM701 in patients with advanced solid tumors. COM701 has been designed to target the PVRIG gene, which according to the Israeli pharma company is a novel immune checkpoint target it had identified […]